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In  a  previous communication  (1) it has been shown that the subcu- 
taneous  or  intravenous  injection  of  monkeys  with  Pneumococcus 
Type I  vaccine confers on them a  complete immunity against experi- 
mental Pneumococcus Type I  pneumonia.  In this article the results 
of similar experiments with Pnettmococcus Types II, III, and IV will 
be reported.  Two species of monkeys have been employed in  these 
experiments, the Philippine Macacus syrichtus and the South American 
Cebus capucinus.  Both species are quite susceptible to pneumococcus 
and  when inoculated  intratracheally  with  a  virulent  culture practi- 
cally always develop pneumonia. 
Methods. 
Ordinary saline  pneumococcus  vaccine was  used for the  experiments.  The 
method of preparation has been described  in Paper I  of this series  (1).  In all 
instances  the monkeys received three subcutaneous  injections of vaccine at inter- 
vals of 5 to 7 days, the total dosage varying from 120 to 200 billion pneumococci. 
The first dose was usually small,  the second and third much larger.  As in the 
previous experiments,  the injections of vaccine were made in the back or abdomen 
and excited only a mild grade of local reaction. 
In testing the immunity of the vaccinated monkeys, the same pneumococcus 
strains were used for the intratracheal injections of living culture that had been 
employed in making the vaccines.  These tests were carried out 2 or 3 weeks 
after the completion of vaccination.  The technique of intratracheal inoculation 
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has also been previously described.  The dose of culture injected in these experi- 
ments varied from 0.1 to 0.000001  cc. for each monkey, depending on the virulence 
of  the  strain.  In  every  experiment  an  unvaccinated  control  was  inoculated 
simultaneously with the vaccinated monkeys, and in every case the control came 
down  promptly with  pneumonia.  Following the inoculations each monkey was 
examined daily, usually for 7 or 8 days.  The rectal temperature was taken twice 
daily  and  leucocyte  counts  and  blood  cultures were made  once a  day.  The 
monkeys that did not die following inoculation with  cultures were killed at  the 
conclusion of the experiment.  Complete autopsies were performed on all animals 
and  microscopic  sections  from  the  lungs  were  studied.  Routine  postmortem 
cultures were taken from the lungs and heart's blood. 
Active Immunity against Pneumococcus Type II Pneumonia Following 
Three Subcutaneous Injectiom  o/Pneumococcus Type II Vaccine. 
The  first  experiment  in  this  study  was  carried  out with  Pneumo- 
coccus  Type  II.  A  virulent  culture,  fatal  for  mice  in  doses  of 
0.00000001  cc. of broth culture, was  used  for  the  preparation  of  the 
vaccine and also for the subsequent  immunity  tests. 
Experiment/.--Three Philippine  monkeys  were  vaccinated  subcutaneously 
as follows: Sept. 3, 1921.  No. 1 (1,654 gin.), No. 2 (1,395 gin.), and No. 3  (2~167 
gin.) received each 10 billion (1 cc.) of Pneumoeoccus Type II vaccine subcutane- 
ously.  Sept.  10.  Each  monkey received  80  billion  (2  cc.)  of  Pneumococcus 
Type II vaccine subcutaneously.  Sept.  17.  Each monkey received 100 billion 
(2 cc.) of Pneumococcus Type II vaccine subcutaneously.  There was no general 
reaction noticeable after any of the injections.  Monkeys 1 and 2 each developed 
a  small hard nodule at the site of the third inoculation.  These nodules disap- 
peared after about 1 week.  Oct. 1 (2 weeks after the third injection of vaccine). 
The  three  vaccinated monkeys and a  control monkey, No. 4  (2,412  gin.),  each 
received  intratracheally  0.1  cc.  of  a  broth  culture  of virulent  Pneumococcus 
Type II. 
The  results  of  this  experiment  are  shown  in  Text-fig.  1.  The  vaccinated 
monkeys reacted with a sudden rise in temperature, which reached its maximum 
about 6 hours after inoculation.  The next morning the temperatures of all three 
vaccinated monkeys were normal and remained so.  In each instance this rise of 
temperature was accompanied by a  temporary increase in the number of leuco- 
cytes.  The monkeys were healthy and lively throughout the experiment and their 
blood cultures  remained  sterile.  The  control monkey became ill  shortly after 
inoculation with the Pneumococcus Type II culture and ran a  typical course of 
lobar  pneumonia  with  marked  leucocytosis  and  pneumococcemia.  All  four 
monkeys were killed on the 7th day after the infecting dose was given.  At a~ttopsy 
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of the vaccinated animals a  few small petechial hemorrhages were found in the 
lungs, but microscopic sections from the loci revealed only red blood corpuscles 
in the alveoli, with no exudation of leucocytes.  Cultures from the hemorrhagic 
areas were sterile.  The control monkey showed  complete consolidation  of the 
right  lower lobe,  with  typical pneumonic  exudate  from which  Pneumococcus 
Type II was isolated in pure culture. 
Protection Tests.--Blood was taken from the  three vaccinated monkeys just 
before their active immunity was tested to determine the protective power of their 
serums in mice.  No protective action could be demonstrated against Pneumo- 
coccus Type II in any of the serums, even when doses as minute as 0.0000001 cc. 
of culture were used. 
From  this  experiment it may be inferred  that  three  subcutaneous 
injections of Pneumococcus  Type II vaccine afford complete protec- 
tion  to monkeys against Pneumococcus  Type II pneumonia. 
Active Immunity against Pneumococcus Type III Pneumonia Following 
Three Subcutaneous Injections  of Pneumococcus Type III Vaccine. 
The  next  problem was  to  determine  the  effectiveness  of prophy- 
lactic vaccination against Pneumococcus Type III pneumonia.  The 
technique  in  the  Type III  experiments was similar in  every respect 
to that employed in the Pneumococcus Type II experiments. 
Experiment 2.--Oct. 18,  1921.  Three Cebus capucinus monkeys, No. 5 (1,500 
gin.), No. 6 (1,250 gm.), and No. 7 (1,432 gm.), received each 20 billion  (0.5 cc.) 
Pneumococcus Type III vaccine subcutaneously.  Oct.  25.  Each  monkey re- 
ceived 40 billion (1 cc.) Pneumococcus Type III vaccine subcutaneously.  Nov. 1. 
Each monkey received 60 billion (1.5 cc.)  Pneumococcus Type III vaccine sub- 
cutaneously.  The monkeys developed small firm nodules at the sites of these 
injections, but no other reaction.  Nov.  15  (2 weeks after the last injection of 
vaccine).  Each  of  the  three  vaccinated monkeys received 0.001  cc.  of an  18 
hour  broth  culture  of  Pneumococcus  Type III  (Hughes)  intratracheally.  An 
unvaccinated control monkey, No. 8  (1,450 gm.), received the same amount of 
culture intratracheally. 
The results of  the  experiment are  shown  in Text-fig. 2.  All  four  monkeys 
showed a rise of temperature following the inoculation with Pneumococcus Type 
III culture, but in the vaccinated monkeys the temperature returned to normal, 
on the 5th or 6th day after inoculation, whereas the control monkey ran a high 
fever until death occurred on the 4th day.  The vaccinated monkeys showed a 
moderate leucocytosis following  the  intratracheal  inoculation.  In  the  control 
monkey a marked leucopenia developed almost at once.  One of the vaccinated 
monkeys, No. 6, had pneumococci in the blood; in the other two the blood cul- RUSSELL  L.  CECIL  AND  GUSTAV  I.  STE]~'IFE~T  153 
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tures remained sterile.  Strangely enough, no pneumococci were found in theblood 
of the control monkey.  The most significant  thing in this experiment was the 
difference in appearance between the vaccinated monkeys and the control.  The 
former remained lively and well during the entire period of observation.  The 
control became very sick at once and died on the 4th day. 
The vaccinated monkeys were killed on the 6th day.  Autopsies showed normal 
lungs in Monkeys 5 and 7.  Several small patches of interstitial pneumonia were 
found in the right lower lobe of No. 6.  The control monkey had a frank con- 
solidation of the right middle and lower lobes.  Postmortem cultures were nega- 
tive in Monkeys 5 and 7.  Cultures from the right lower lobe of No. 6 yielded 
Pneumococcus  Type  III.  Cultures  from  the  control  were  overrun  with  B. 
bronchisepticus, but  a  few  Gram-positive diplococci  were  seen  in  microscopic 
sections stained for bacteria. 
Protection Tests.--Blood from the three vaccinated monkeys showed no pro- 
tective bodies against Pneumococcus Type III in mice. 
In  this  experiment  complete  protection  against  Pneumococcus 
Type  III  was  obtained  in  two  of  the  vaccinated  monkeys,  partial 
protection in  the  third.  It is hard  to explain why these vaccinated 
monkeys, though immune to pneumonia, sometimes show a temporary 
rise in temperature following inoculation with the living culture.  In 
some  instances  an  acute  bronchitis  is  excited  which,  however,  does 
not develop into pneumonia.  In others the fever may be the expres- 
sion of a  foreign protein reaction. 
A  second experiment was carried out with Pneumococcus Type III 
vaccine in the hope of obtaining complete protection in all the vacci- 
nated  monkeys.  In  this  experiment  larger  doses  of  vaccine  were 
employed. 
Experiment 3.--Jan. 23,  1922.  Three Cebus capucinus monkeys, No.  9 (1,328 
gm.), No. 10 (1,360 gm.), and No. ll  (1,244 gm.), received each 1 billion  (lcc.) 
Pneumococcus Type III vaccine (Hughes) subcutaneously.  Jan. 28.  Each mon- 
key received  80 billion  (1  cc.) Pneumococcus  Type III vaccine  subcutaneously. 
Feb. 1.  Each monkey received 120 billion Pneumococcus Type III vaccine  sub- 
cutaneously.  Feb. 13.  No. 9 has developed a small ulcer at the site of the last 
inoculation.  The other monkeys show only the usual small nodules.  Feb. 14 (2 
weeks after the third  injection  of vaccine).  Each  monkey received 0.1  cc.  of 
an 18 hour broth culture of Pneumococcus Type III (Hughes) intratracheally. 
An unvaccinated monkey, No. 12 (1,840 gin.), received the same amount (0.1 cc.) 
of culture intratracheally. 
The results are shown in Text-fig. 3.  Monkey l l  remained lively and well. 
There was a temporary rise in temperature, but the leucocytes were normal and RUSSELL  L.  CECIL  AND  GUSTAV  I.  STEFFEN  155 
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the blood culture remained sterile.  The other two vaccinated monkeys became 
ill, developed a leucopenia and heavy, pneumococcemia and died, one on the 5th 
and the other on the 7th day of the disease.  The control monkey died the day 
after inoculation  with  an  overwhelming pneumococcemia. 
Autopsies were performed on all four monkeys.  Monkey  11  showed  a  few 
petechial hemorrhages in  the lungs,  but no consolidation.  Monkeys 9  and  10 
both had lobar pneumonia, the former in the right lower lobe, the latter in both 
the right and left lower lobes.  The control monkey, No.  12,  showed  an early 
lobar pneumonia in the right lower lobe and several partly healed foci of pul- 
monary tuberculosis.  Postmortem cultures from the lungs and heart's blood of 
Monkeys 9, 10, and 12 yielded Pneumococcus Type III.  Cultures from Monkey 
11 were negative, except for a few colonies of Pneumococcus Type III which were 
found on cultures from the trachea. 
In this experiment only one of the three vaccinated monkeys resisted 
infection with Pneumococcus Type III.  The other  two developed a 
Pneumococcus  Type  III  pneumonia.  A  careful  study  of  the  pro- 
tocols  indicates  that  too  large  an  infecting  dose  was  used  in  this 
experiment.  This  is  shown  by  the  fulminating  course  which  the 
infection  pursued  in  the  control.  As  it  was,  the  two  vaccinated 
monkeys  that  developed  pneumonia  lived  several  days  longer  than 
the  unvaccinated  monkey. 
One  more  Type  III  experiment  was  undertaken,  this  time  with 
another  strain  of pneumococcus. 
Experiment 4.--June 16, 1922.  Two Cebus capucinus monkeys, No. 13 (1,200 
gin.)  and No. 14 (1,550 gin.),  received each 12 billion (1 cc.) Pneumococcus Type 
III  (Bowen)  vaccine  subcutaneously.  June  23.  Each  monkey  received  50 
billion  (2  cc.)  Pneumococcus  Type  III  vaccine  subcutaneously.  June  30. 
Each monkey received 138 billion  (2 cc.)  Pneumococcus Type III vaccine sub- 
cutaneously.  July  18  (2½ weeks after the last injection of vaccine).  The two 
vaccinated monkeys and a  control monkey, No.  15  (2,600  gm.), each received 
0.001  cc.  of  an  18  hour  broth  culture  of  Pneumococcus  Type  III  (Bowen) 
intratracheally. 
Monkey 13 remained lively and well, but Monkey 14 became moderately sick. 
The control monkey, No.  15, became quite sick, and probably would have died 
had it not been killed on the 8th day.  Text-fig. 4 shows  the temperature, leu- 
cocyte, and blood culture curves.  Monkey 13 showed no changes in temperature 
or  leucocyte  count,  and  the  blood  remained  sterile.  Monkey  14  developed 
no fever, but  the  leucocytes rose,  and pneumococci  appeared  in  the  blood in 
moderate numbers on the 7th day of observation.  The control monkey ran a high 
fever, the leucocytes rose to 29,600, and a heavy pneumococcemia appeared on 
the 4th day following  inoculation. RUSSELL  L. 
; 
CM 
(N 
(',1 
o4 
0 
oJ 
o3 
CECIL  AND  GUSTAV  I.  STEFFEN 
Pneu.mococc~ in ice. of  Mood.  o--..~ 
o 
.,-t  ~o  0 
l/>  I~l 
TIT" d'~I ~O0'C -- 
J 
i, 
,4 
> 
o,  i, 
I 
I 
I 
I 
I 
I 
[ 
k.." 
i 
L  F 
~z'~a 'o0 ~00'0  --~ 
o  o  o_.  o_  2  o  £  N 
~ a~x~,~oao du.t a j_ 
o  °  g  o  o  o  o 
o 
9  9  o~°  8- 
~d  ,...-=, 
157 
~F~m 
0~  ~ o 
¢,;, 
~0 
¢:h,,  o 
,~  <-~ 158  STUDIES  ON  PNEUMOCOCCUS IM~UNITY.  II 
All three monkeys were killed on the 8th day.  No. 13 showed normal lungs; 
1%o. 14 presented several small patches of consolidation in both lower lobes.  The 
control, No. 15, showed an interstitial pneumonia of the right lower lobe.  Post- 
mortem cultures from the lungs  and heart's blood of Monkey 13 were sterile. 
Monkey 14 and the control both yielded Pneumococcus Type III from the heart's 
blood and also from the consolidated areas in the lungs. 
Protection Tests.--Protection tests with blood from the two vaccinated monkeys 
were carried out on mice, but no protective substance could be demonstrated in 
either monkey. 
This experiment, like  the  two preceding ones with Pneumococcus 
Type III,  was  not entirely successful in  that  one  of the  vaccinated 
monkeys was not sufficiently immune to resist infection.  In view of 
the difficulties experienced by previous workers in immunizing animals 
against Pneumococcus Type III, we had  expected to meet with less 
success with Type III than with the other types.  Altogether, eight 
monkeys  were  vaccinated  against  Pneumococcus  Type  III.  Four 
of them resisted infection and four developed Type III pneumonia. 
Active Immunity against Pneumococcus Type IV Pneumonia Following 
Three Subcutaneous Injections of Pneumococcus Type IV Vaccine. 
Pneumococcus Type IV is  really not a  type  but a  heterogeneous 
group of pneumococci that do not fall into any one of the three fixed 
types.  The  so  called  Type  IV  strains  rarely  cross-agglutinate  or 
cross-protect, but it seemed desirable to carry out one Type IV experi- 
ment on monkeys, using the same strain of pneumococcus for vaccine 
and for testing the immunity. 
Experiment 5.--May  29,  1921.  Three Macacus syrichtus monkeys,  No.  16 
(1,775 gin.), No. 17 (1,430 gm.), and No. 18 (1,410 gin.), received each 20 billion 
(0.5 cc.) Pneumococcus Type IV vaccine subcutaneously.  June 4.  Each monkey 
received 40 billion (1 cc.) Pneumococcus Type IV vaccine subcutaneously.  June 
11.  Each monkey received 60 billion  (1  cc.)  Pneumococcus  Type IV vaccine 
subcutaneously.  June 28 (2½ weeks after the last injection of vaccine).  Each 
monkey received 0.00001 cc. of an 18 hour broth culture of Pneumococcus Type 
IV intratracheally.  At the same  time, an unvaccinated control, No.  19 (2,300 
gin.), received the same amount of culture intratracheally. 
The results are shown in Text-fig. 5.  The three vaccinated monkeys remained 
perfectly well.  There was no noteworthy rise in the temperature or leucocyte 
count, and the blood cultures remained sterile.  The control monkey showed a 
slight rise in temperature, the leucocytes jumped from 17,000 to 32,000 and the RUSSELL  L. CECIL AND  GUSTAV I.  STE]~]~EN  159 
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blood cultures yielded Pneumococcus  Type IV on the 3rd and 4th days of  the 
disease.  During this period the control was very quiet but did not appear acutely 
ill. 
On the 6th day all four monkeys were killed.  The three vaccinated monkeys 
were found to have normal lungs.  The control monkey showed small patches of 
interstitial pneumonia in the right lower and the left upper lobes.  Postmortem 
cnltures from the lungs of the vaccinated monkeys were sterile.  Cultures  from 
the patches in the lungs of the control yielded Pneumococcus Type IV. 
Protection Tests.--Serum was collected  from the three immunized  monkeys  just 
before the immunity test was made, and protection tests against the homologous 
strain of Pneumococcus  Type IV were carried out on mice.  No protective bodies 
could be demonstrated in any of the three serums. 
This experiment would have been more convincing if the control 
had shown a  more extensive pneumonia.  However, pneumonia was 
present in the control and absent in the three vaccinated monkeys,- 
evidence enough to show that active immunity could be established 
against  Pneumococcus Type  IV  as  well  as  against  the  three  fixed 
types. 
DISCUSSION. 
It was reasonable to suppose that if monkeys could be immunized 
against Pneumococcus Type I, they could also be immunized against 
the  other  three  types, for the pneumococci all belong  to  the  same 
biological species and have almost identical morphological and cultural 
characteristics.  It is only in respect to immunological traits that they 
vary among themselves. 
It is more difficult to obtain a high immunity against Pneumococcus 
Type III than it is against the other types.  It is possible that the 
thick capsule which characterizes this type may interfere in some way 
with the release of the antigen and the consequent stimulation of the 
mechanism which produces the immune substance.  The same factor 
that prevents the development of a  high active immunity may also 
be responsible for the high death rate in Type III pneumonia in man. 
In the one instance, killed pneumococci, in the other, living pneumo- 
cocci,  fail to stimulate a  sufficiently sharp response by the immune 
mechanism. 
31onkeys tolerate large doses of pneumococcus vaccine remarkably 
well.  In the present study the local reactions were insignificant and 
constitutional reactions were slight or entirely absent. RUSSELL  L.  CECIL  AND  GUSTAV  I. STEFFEN  161 
In the experiments with Pneumococcus Type I, previously reported, 
three subcutaneous injections of monkeys with Pneumococcus Type 
I  vaccine often stimulated the production of specific protective sub- 
stance in the blood of the vaccinated monkeys.  In a  similar way, 
protective bodies could be demonstrated after three intravenous injec- 
jections of Type I  vaccine.  In the experiments with Pneumococcus 
Types II, III, and IV, three subcutaneous injections of vaccine failed 
in every instance to produce protective substance in the blood, even 
when the  monkey was immune to infection.  Evidently it  is  more 
difficult to stimulate protective bodies against Types II, III, and IV 
than against Type I.  Judging from experience with other  animals, 
however, protective bodies against all  types could be developed in 
monkeys ff repeated injections of vaccine were administered either 
subcutaneously or intravenously. 
CONCLUSIONS. 
1.  Three subcutaneous injections of Pneumococcus Type II vaccine 
confer on monkeys a  complete immunity against experimental Pneu- 
mococcus Type II pneumonia.  A similar protection can be bestowed 
on monkeys against Pneumonococcus Type IV pneumonia by three 
subcutaneous injections of a  vaccine prepared from the same strain 
of pneumococcus. 
2.  The  subcutaneous  injection  of  monkeys with  three  doses  of 
Pneumococcus Type III vaccine confers a complete immunity against 
this  type in only 50  per cent of cases  (four out of  eight monkeys 
vaccinated). 
3.  In  spite  of  the immunity induced in monkeys by  three  sub- 
cutaneous injections of Pneumococcus Types II, III, and IV vaccine, 
specific protective bodies against the homologous types are not demon- 
strable in their serums when the vaccine is so administered. 
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